{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=96", "query": { "condition": "Advanced Solid Neoplasm", "page": 96 }, "page_size": 10 }, "pagination": { "page": 96, "page_size": 10, "total_count": 3387, "total_pages": 339, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=97&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=95&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T23:54:21.783Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05462717", "title": "Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Pancreatic Ductal Adenocarcinoma", "Advanced Solid Tumor" ], "interventions": [ { "name": "RMC-6291", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2022-09-19", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-11-14T23:54:21.783Z", "location_count": 15, "location_summary": "Springdale, Arkansas • Orange, California • Sacramento, California + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462717" }, { "nct_id": "NCT01831089", "title": "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Gynecological Cancer", "Head and Neck Carcinoma", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Non-squamous Cell Lung Cancer" ], "interventions": [ { "name": "PM01183 + paclitaxel +/- bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 69, "start_date": "2013-09", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2020-04-10", "last_synced_at": "2026-11-14T23:54:21.783Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01831089" }, { "nct_id": "NCT05340621", "title": "NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "RAS Mutation", "NRAS Gene Mutation", "Melanoma" ], "interventions": [ { "name": "OKI-179 + binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OnKure, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2022-05-11", "completion_date": "2025-01-29", "has_results": false, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-11-14T23:54:21.783Z", "location_count": 12, "location_summary": "Phoenix, Arizona • San Francisco, California • Gainesville, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05340621" }, { "nct_id": "NCT07020221", "title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Non Small Cell Lung Cancer", "Colorectal Cancer", "Solid Tumor, Adult", "G12D Mutated KRAS" ], "interventions": [ { "name": "VS-7375", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Carboplatin + Pemetrexed + Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine + Nab-paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Defactinib", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verastem, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 616, "start_date": "2025-06-24", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-14T23:54:21.783Z", "location_count": 13, "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07020221" }, { "nct_id": "NCT06421935", "title": "M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "M9466", "type": "DRUG" }, { "name": "Tuvusertib", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-08-07", "completion_date": "2027-02-22", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-11-14T23:54:21.783Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06421935" }, { "nct_id": "NCT06452160", "title": "A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma", "Epithelioid Hemangioendothelioma(EHE)", "Solid Tumor" ], "interventions": [ { "name": "BGC515", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BridGene Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2024-06-27", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-11-14T23:54:21.783Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06452160" }, { "nct_id": "NCT07046923", "title": "A Study of LY4175408 in Participants With Advanced Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Small Cell Lung Carcinoma", "Endometrial Neoplasms", "Neoplasm Metastasis", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "LY4175408", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2025-07-28", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-14T23:54:21.783Z", "location_count": 15, "location_summary": "Stanford, California • Orlando, Florida • Sarasota, Florida + 11 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07046923" }, { "nct_id": "NCT07395258", "title": "A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "BI 3923948", "type": "DRUG" }, { "name": "Ezabenlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-04-02", "completion_date": "2032-02-12", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-14T23:54:21.783Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Minneapolis, Minnesota", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07395258" }, { "nct_id": "NCT04439110", "title": "Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2015-08-12", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-11-13", "last_synced_at": "2026-11-14T23:54:21.783Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439110" }, { "nct_id": "NCT05007782", "title": "Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Denikitug", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 304, "start_date": "2021-08-18", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-11-14T23:54:21.783Z", "location_count": 10, "location_summary": "La Jolla, California • Palo Alto, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05007782" } ] }